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Supplementary Table 1: Comparison of baseline characteristics between mothers whose offspring underwent DXA assessment and mothers whose offspring did not.  
 
Without DXA With DXA p difference 
N 469 665  
Age (years), mean±SD 30.0 ± 5.4 30.8 ± 5.0 0.01 
Ethnicity, % Caucasian 92.9 95.0 0.15 
Parity, % nulliparous 44.5 43.2 0.68 
Current smoker, % 10.2 6.9 0.05 
Educational attainment ≥ A level, % 73.7 78.6 0.07 
Walking speed at least fairly brisk, % 38.7 40.2 0.63 
Strenuous exercise ≥ once week, % 14.5 15.1 0.81 
Height (cm), mean±SD 165.7 ± 6.6 165.6 ± 6.4 0.77 
Weight (kg), median (IQR) 70.4 (63-82.3) 69.3 (61.8-79.6) 0.1 
BMI (kg/m2), median (IQR) 25.6 (22.8-30.2) 24.9 (22.5-29.0) 0.1 
Sum of all skinfold (mm), mean±SD 84.7 ± 27.4 80.0 ± 28.1 0.01 
25(OH)D (nmol/l), mean±SD 47.1 ± 18.6 45.8 ± 16.5 0.22 
25(OH)D>50nmol/l, % 41.1 37.8 0.28 
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Supplementary Table 2: Baseline characteristics by randomisation group and season.  
 
  
  Placebo Cholecalciferol (1000 
IU/day) 
Placebo Cholecalciferol (1000 
IU/day) 
Placebo Cholecalciferol 
(1000 IU/day) 
Placebo Cholecalciferol 
(1000 IU/day) 
 
WINTER SPRING SUMMER AUTUMN 
N 102 104 126 120 130 122 128 133 
Age (years), mean±SD 30.5 ± 5.4 30.5 ± 5.4 30.7 ± 5.0 30.4 ± 5.5 30.4 ± 5.1 31.2 ± 4.6 31.1 ± 5.3 30.9 ± 5.0 
Ethnicity, % Caucasian 93.1 96.2 94.4 95.0 92.1 96.7 97.3 94.1 
Parity, % nulliparous 43.6 46.2 46.0 47.1 41.3 37.2 45.5 41.2 
Current smoker, % 10.0 6.8 7.1 11.8 6.3 5.0 7.1 8.3 
Educational attainment ≥ A 
level, % 71.3 75.7 80.0 79.8 77.6 76 77.5 80.8 
Walking speed at least fairly 
brisk, % 40.0 37.4 46.4 44.9 42.5 29.8 39.8 38.4 
Strenuous exercise ≥ once week, 
% 20.0 20.9 14.4 12.8 13.4 15.7 10.7 16.2 
Height (cm), mean±SD 165.3 ± 6.9 164.7 ± 6.1 166.5 ± 7.2 166.1 ± 6.8 165.7 ± 6.3 165.3 ± 5.7 165.3 ± 6.1 165.9 ± 6.3 
Weight (kg), median (IQR) 68.4 (62.7-80.7) 68.7 (61.2-77.7) 70.5 (63.8-80.5) 69.5 (61.0-81.6) 70.7 (63.3-80.2) 67.1 (59.7-78.3) 72.7 (63.1-83.0) 69.0 (61.3-77.0) 
BMI (kg/m2), median (IQR) 25.0 (22.7-26.7) 24.6 (22.4-28.8) 25.0 (22.6-28.5) 24.9 (22.1-28.9) 25.6 (23.0-29.3) 24.9 (22.5-28.3) 26.5 (23.1-30.3) 24.6 (22.1-28.7) 
Sum of all skinfold (mm), 
mean±SD 78.8 ± 27.6 80.6 ± 25.6 83.7 ± 27.4 81.0 ± 30.4 85.1 ± 27.6 78.1 ± 28.8 85.8 ± 27.9 79.8 ± 27.7 
25(OH)D (nmol/l), mean±SD 53.7 ± 16.1 54.7 ± 18.9 43.6 ± 15.7 46.2 ± 16.7 40.7 ± 16.8 42.8 ± 17.1 46.4 ± 16.7 44.7 ± 14.9 
25(OH)D>50nmol/l, % 61.0 56.4 33.6 38.5 22.8 32.5 35.0 38.6 
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Supplementary Table 3: Neonatal anthropometry, bone mineralisation and body composition by season of birth in infants born to mothers randomised to placebo or 
1000IU/day cholecalciferol in pregnancy. Shown as mean (SD), unless otherwise stated.  
  Placebo Cholecalciferol (1000IU/day) 
 Season of birth Winter Spring Summer Autumn p Winter Spring Summer Autumn p 
Obstetric data 
          
Males, N(%) 53 (52.0) 68 (54.0) 65 (50.0) 65 (50.8) 0.93 59 (56.7) 55 (45.8) 66 (54.1) 78 (58.7) 0.20 
Birth weight (g) 3407 ± 430 3560 ± 560 3575 ± 493 3508 ± 551 0.07 3507 ± 545 3462 ± 622 3486 ± 510 3473 ± 496 0.94 
Crown-heel length (cm) 50.6 ± 1.9 50.5 ± 2.5 51.0 ± 2.2 51.1 ± 2.3 0.11 50.6 ± 2.2 50.3 ± 3.1 50.7 ± 2.8 50.9 ± 1.9 0.51 
Head circumference (cm) 35.0 ± 1.3 35.4 ± 1.4 35.6 ± 1.6 35.6 ± 1.4 0.02 35.4 ± 1.2 35.4 ± 1.5 35.4 ± 1.4 35.4 ± 1.4 0.99 
Abdominal circumference (cm) 32.0 ± 2.0 32.7 ± 2.5 33.0 ± 2.3 32.8 ± 2.3 0.06 32.6 ± 2.2 32.9 ± 2.3 33.2 ± 2.3 32.9 ± 2.2 0.39 
DXA                     
Bone Area (cm2) 289.4 ± 35.3 299.0 ± 39.9 301.2 ± 37.6 299.6 ± 35.2 0.25 300.9 ± 31.3 305.2 ± 40.6 303.9 ± 32.6 296.5 ± 33.4 0.36 
BMC (g) 57.5 ± 10.9 60.8 ± 12.1 60.7 ± 10.6 62.3 ± 10.4 0.07 63.0 ± 10.8 62.3 ± 14.1 61.2 ± 10.4 60.2 ± 11.0 0.45 
BMD (g/cm2) 0.200 ± 0.019 0.202 ± 0.019 0.201 ± 0.020 0.207 ± 0.019 0.11 0.208 ± 0.024 0.202 ± 0.024 0.200 ± 0.019 0.202 ± 0.019 0.17 
Lean (g) 2955 ± 415 2968 ± 472 3073 ± 423 3049 ± 411 0.26 3074 ± 428 3063 ± 478 3063 ± 396 3023 ± 393 0.87 
Fat (g), median (IQR) 324 (210-428) 440 (267-617) 378 (243-497) 379 (268-501) 0.02 378 (271-516) 373 (264-645) 360 (211-553) 302 (218-470) 0.27 
 
Amongst infants born to mothers who received placebo, statistically significant differences in head circumference and total fat mass across the birth seasons were identified 
such that head circumference and fat mass were lower in winter.  In contrast, these differences were not observed in infants of mothers who received vitamin D 
supplementation 
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Supplementary Table 4: Mean (95% CI) neonatal whole body bone mineral content by treatment group and month of birth [winter= December, January, February] 
  
 
Placebo 
 
1000 IU/d 
Month of Birth 
 
n Mean 95%CI 
 
n Mean 95%CI 
December 16 56.7 45.1-65.4 17 62.3 55.1-67.3 
January 27 56.2 50.4-61.9 29 62.6 58.8-66.6 
February 21 59.7 52.6-67.6 28 63.7 57.2-69.1 
March 26 59.8 50.3-67.4 24 59 52.8-67.5 
April 27 60.8 53.4-67.4 29 58.2 47.3-69.2 
May 45 61.3 52.5-71.8 31 68.6 59.6-79.2 
June 33 61.1 56.1-68.1 40 62.3 54.7-67.1 
July 18 62 57.0-66.5 25 60.1 55.0-65.9 
Aug 28 59.4 51.6-65.9 26 60.7 53.5-68.1 
Sep 31 60 54.0-66.2 32 55.7 48.2-60.9 
Oct 25 63 57.8-68.3 23 65.8 58.3-74.0 
Nov 30 64.1 58.1-71.9 34 60.6 52.4-69.3 
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Supplementary Table 5: Mean (95%CI) bone outcomes in cholecalciferol and placebo groups stratified by 14 week 25(OH)D above versus below the median (45.1 nmol/l). 
14 week 25(OH)D Placebo Cholecalciferol (1000IU/day) p- difference
a p-interactionb 
nmol/l Mean (95%CI) Mean (95%CI  
 
 BA (cm
2)   
< 45.1 297.0 (290.9-303.1) 302.5 (297.2-307.7) 0.18 0.20 
≥ 45.1 298.6 (293.0-304.2) 300.8 (295.3-306.2) 0.58  
 BMC (g)   
< 45.1 60.9 (59.2-62.7) 61.9 (60.2-63.7) 0.42 0.67 
≥ 45.1 60.1 (58.4-61.8) 61.3 (59.5-63.1) 0.36  
 BMD (g/cm
2)   
< 45.1 0.204 (0.201-0.207) 0.203 (0.200-0.206) 0.60 0.53 
≥ 45.1 0.201 (0.198-0.204) 0.202 (0.199-0.206) 0.59  
 BMC for height (g)   
< 45.1 61.2 (59.4-63.0) 62.2 (60.4-63.9) 0.45 0.57 
≥ 45.1 59.9 (58.2-61.6) 61.1 (59.3-62.9) 0.33  
a p-value for difference between cholecalciferol and placebo groups; b p-value for interaction between treatment and baseline 25(OH)D.  
 
When stratified by median 14 week 25(OH)D in the whole cohort (45.1nmol/l), differences in BA, BMC and BMC for length did not achieve statistical significance either 
above or below the median. Tests for interaction between baseline 25(OH)D (above vs below median) and group (cholecalciferol 1000IU/day vs placebo) were also non-
significant. 
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Supplementary Table 6: Mean (SD) 25(OH)-vitamin D concentration at 14 and 34 weeks in treatment and placebo groups by a) season of birth and b) by individual month 
of birth. 
 
 a Placebo 1000 IU/d 
  14 week 25(OH)D 34 week 25(OH)D 14 week 25(OH)D 34 week 25(OH)D 
Season of birth Mean SD Mean SD Mean SD Mean SD 
Winter 53.7 16.1 30.3 15.6 54.7 18.9 62.4 22.6 
Spring 43.6 15.7 32.9 19.7 46.2 16.7 64.5 24.6 
Summer 40.7 16.8 48.9 18.3 42.8 17.1 72.1 19 
Autumn 46.4 16.7 58.2 22.3 44.7 14.9 72 20.3 
         
 b Placebo 1000 IU/d 
  14 week 25(OH)D 34 week 25(OH)D 14 week 25(OH)D 34 week 25(OH)D 
Month of Birth Mean SD Mean SD Mean SD Mean SD 
January 57.3 14.2 33.0 16.1 54.3 18.0 65.2 16.6 
February 50.4 18.0 24.5 14.5 52.9 19.0 56.2 25.7 
March 45.4 16.5 31.7 19.6 49.2 17.2 57.4 25.0 
April 46.5 15.1 30.3 21.7 49.2 17.5 67.8 23.3 
May 40.6 15.3 34.7 18.8 40.8 14.3 66.8 25.1 
June 39.4 16.9 39.3 17.0 41.3 16.9 68.4 17.9 
July 44.1 18.3 51.6 15.4 40.8 16.7 69.2 16.3 
August 39.2 15.3 56.6 17.8 46.7 17.7 79.0 20.7 
September 42.1 16.4 62.8 25.6 44.7 15.1 73.0 18.9 
October 45.7 15.7 59.8 19.3 43.9 14.9 75.9 21.7 
November 52.2 16.7 52.2 20.8 45.3 14.8 68.0 20.5 
December 52.2 15.9 32.9 14.8 57.4 20.2 66.6 23.5 
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Supplementary Table 7: Frequency of non-protocol vitamin D supplement use (up to 400 IU per day) by treatment group and season of birth.  
  
% who used additional vitamin D 
supplements   
Season of birth 
Placebo Cholecalciferol 
(1000 IU/day) 
p difference 
Winter 22.6 25.0 0.68 
Spring 23.8 23.3 0.93 
Summer 24.6 25.4 0.88 
Autumn 26.6 27.1 0.93 
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. Supplementary Table 8: Maternal weight and skinfold thicknesses at 34 weeks’ gestation by treatment group and season of offspring birth. Data are the mean (95% CI) 
difference in the maternal measure between treatment and placebo group. 
  
Skinfold thickness (mm) 
 
Weight (kg) Triceps Biceps Subscapular Upper suprailiac 
Season of birth β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) 
Winter 0.20 (-3.97 to 4.39) 0.65 (-1.45 to 2.75) -0.42 (-2.09 to 1.25) 2.00 (-1.37 to 5.38) 2.07 (-0.94 to 5.08) 
Spring 0.14 (-3.70 to 3.98) -0.22 (-2.25 to 1.80) 0.19 (-1.21 to 1.59) -0.48 (-3.58 to 2.62) 0.52 (-2.25 to 3.28) 
Summer -2.28 (-6.14 to 1.57) -1.41 (-3.36 to 0.53) -0.70 (-2.17 to 0.76) -1.73 (-4.35 to 0.89) -0.52 (-3.38 to 2.35) 
Autumn -4.62 (-7.93 to -1.31) -1.61 (-3.43 to 0.21) -1.62 (-3.12 to -0.11) -1.34 (-4.01 to 1.32) -2.13 (-4.70 to 0.44) 
p interaction 0.22 0.37 0.38 0.34 0.23 
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Supplementary Table 9: Absolute numbers and percentages of adverse events and serious adverse events by 
treatment group. 
 
Placebo 
Cholecalciferol 
(1000IU/day) 
p- difference 
 
N (%) N (%) 
 
Adverse events 
   
Infection 17 (3.0) 17 (3.0) 0.98 
Nausea/vomiting 7 (1.2) 6 (1.1) 0.79 
Diarrhoea 4 (0.7) 6 (1.1) 0.52 
Abdominal pain 19 (3.3) 16 (2.8) 0.62 
Headache 9 (1.6) 8 (1.4) 0.82 
Hypertension 15 (2.6) 13 (2.3) 0.72 
Hypercalcaemia (≥ 2.75 mmol per l) at 34 weeks gestation 0 0 
 
Fetal growth retardation 0 0 
 
    
Severe adverse events 
   
Preterm delivery / Premature birth 10 (1.8) 16 (2.8) 0.23 
Instrumental delivery 35 (6.2) 25 (4.4) 0.19 
Severe postpartum haemorrhage 96 (16.9) 65 (11.5) 0.01 
Intrauterine or neonatal death 3 (0.5) 1 (0.2) 0.32 
Congenital abnormalities 5 (0.9) 8 (1.4) 0.4 
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Supplementary Figure 1: Neonatal whole body bone area; bone mineral content; bone mineral density; and 
bone mineral content adjusted for birth length, in offspring of women randomised to 1000IU/day cholecalciferol 
or placebo during pregnancy. 
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Supplementary Figure 2: Neonatal whole body bone mineral content adjusted for birth length in offspring of 
women randomised to 1000IU/day cholecalciferol or placebo during pregnancy, stratified by season.  
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Supplementary Figure 3: Neonatal whole body fat and lean in offspring of women randomised to 
1000IU/day cholecalciferol or placebo during pregnancy, stratified by season.  
 
Whole body fat mass 
 
 
Whole body fat mass appeared similar amongst offspring of treatment and placebo mothers for births in spring, 
summer and autumn. However offspring of mothers in the cholecalciferol group who delivered during winter 
had greater whole body fat mass than offspring of mothers receiving placebo: 450 (95%CI: 389.4-510.6) g 
versus 336.4 (95%CI: 283.1-389.8) g, p=0.008. However, the test for interaction between treatment group and 
season on whole body fat was not statistically significant (p = 0.28). This result is consistent with previous 
findings from the Southampton Women’s Survey in which positive associations between maternal 25(OH)D 
concentrations during pregnancy and offspring fat mass at birth were observed. However the relationship was 
equivocal when the child was 4 years old, and became negative at 6 years, such that greater maternal gestational 
25(OH)D was associated with reduced offspring fat mass in later childhood1. Also consistent with findings from 
the Southampton Women’s Survey2, whole body lean mass was greater (albeit not significantly) in offspring 
born to mothers randomised to cholecalciferol compared with placebo amongst winter and spring deliveries 
[winter: 3074 (95%CI: 2974-3175) g vs 2955 (95%CI: 2843-3067) g; p = 0.12) and spring: 3063 (95%CI: 2957-
3169) g versus 2968 (2871-3065) g; p = 0.19]. There was no difference in lean mass by treatment group 
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amongst offspring born in summer and autumn months, and the treatment group by season interaction term for 
whole body lean did not achieve statistical significance (p = 0.35). 
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Supplementary Figure 4: Plasma 25(OH)D at 14 weeks’ gestation by date of collection. 
 
 
 
Baseline 25(OH)D status was similar in both groups and varied by season. Supplementary Figure 4 
demonstrates 14 week plasma 25(OH)D concentration by date of sampling across the duration of recruitment 
into the study. There was a clear sinusoidal distribution in relation to season (p<0.001for fit to Fourier model) 
with summer peaks and winter nadirs. Fourier analysis undertaken as per Crozier et al., Am J Clin Nutr 2012: A 
form of Fourier analysis was used to model the association  
between vitamin D status and date of sample to take account of the cyclical variation in 25(OH)D concentration 
by season1. A variable was derived that described the number of years the sample was taken after the first 
sample in the study and multiplied by 2p to give a value h, in radians. Maternal serum 25(OH)D concentration 
was regressed on cos h and sin h (representing one cycle per annum), on cos 2h and sin 2h (representing 2 
cycles per annum), and on cos 3h and sin 3h (representing 3 cycles per annum). The most parsimonious model 
was the regression of maternal serum 25(OH)D on cos h, sin h, cos 2h, and sin 2h.  
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Supplementary Figure 5:  Plasma 25(OH)D concentrations at 34 weeks’ gestation by date of collection, among 
mothers randomised to (a) placebo, and (b) vitamin D supplementation. 
 
(a) Placebo 
 
 
(b) Cholecalciferol 1000IU/day 
 
 
The maternal plasma 25(OH)D concentrations in late pregnancy showed statistically significant sinusoidal 
distributions (p<0.01) using Fourier transformation in both treatment and placebo groups, but the supplemented 
mothers had higher average values in late pregnancy, and a marked reduction in seasonal amplitude resulting 
from correction in trough values during pregnancies which completed during winter months. 
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